Financial Data and Key Metrics Changes - Fourth quarter total revenue increased by 17% year-over-year to $127.6 million, with full year revenues growing 15% to $460.2 million [16][19] - Loss from operations improved by 19% for the full year to $229.4 million, and improved by 25% when adjusted for non-cash expenses [21] Business Line Data and Key Metrics Changes - The China business provided stability, with full year revenue growth of 15% year-over-year [6] - XACDURO and NUZYRA contributed significantly to revenue growth, with strong patient demand and market coverage [19] Market Data and Key Metrics Changes - The oncology market is expected to see significant opportunities, with Zoci targeting a total addressable market exceeding $9 billion [11] - The company anticipates a potential accelerated approval submission for Zoci in 2027 and a first global approval in 2028 [10] Company Strategy and Development Direction - The company is focused on building a globally competitive oncology and immunology pipeline, with a clear path toward U.S. approval by 2028 for Zoci [5][11] - Business development remains a key lever, with targeted collaborations to explore novel combination strategies [15] Management's Comments on Operating Environment and Future Outlook - Management highlighted a challenging macro and operating environment but expressed confidence in the execution and preparation for 2026 [6] - The company aims to maintain commercial profitability while investing in high-value global programs [44] Other Important Information - The company ended the quarter with a strong cash position of $790 million, positioning it well for future growth [21] - The focus for 2026 includes maintaining the strength of existing business while preparing for multiple growth opportunities [18] Q&A Session Summary Question: Revenue and expenses outlook for 2026 - Management expects good growth opportunities for VYVGART and steady performance from ZEJULA, with modest investments required for launches [24][25] Question: Zoci's intracranial activity implications - Zoci shows high response rates in patients with untreated brain metastases, which is a significant advantage [28][29] Question: U.S.-China development model - The company leverages efficient development structures in China to accelerate timelines and enhance global trial participation [33][34] Question: KarXT commercialization strategy - The commercial launch of KarXT is planned for the second quarter of 2026, focusing on building physician experience and a commercial team [73] Question: Zoci phase 3 trial design - The company plans to start the first-line study by the end of the year, aiming to spare chemotherapy while assessing durability [85]

Financial Data and Key Metrics Changes - Fourth quarter total revenue increased by 17% year-over-year to $127.6 million, driven by strong contributions from XACDURO and NUZYRA [20] - Full year revenues grew by 15% to $460.2 million, reflecting steady progress across the commercial portfolio [20] - Loss from operations improved by 19% for the full year to $229.4 million, with a 25% improvement when adjusted for non-cash expenses [21] Business Line Data and Key Metrics Changes - The China business provided stability, with full year revenue growth of 15% year-over-year [6] - XACDURO performance reflected strong patient demand and expanding hospital adoption, although supply constraints limited full realization of demand [20] - VYVGART showed strong physician confidence and stable patient demand, with expectations for continued growth in 2026 [17] Market Data and Key Metrics Changes - The global oncology market presents a significant opportunity, with an estimated total addressable market exceeding $9 billion for Zoci in small cell lung cancer and neuroendocrine carcinomas [11] - The U.S. market for small cell lung cancer has approximately 15,000 patients available for second-line treatment and 25,000 for first-line treatment [61] Company Strategy and Development Direction - The company aims to build a globally competitive pipeline, focusing on execution and preparation for multiple growth opportunities in 2026 [5][19] - Business development remains a key lever, with targeted collaborations to explore novel combination strategies in oncology [17] - The company is leveraging its presence in China to access a fast-evolving innovation ecosystem, enhancing its global and regional pipeline [8] Management's Comments on Operating Environment and Future Outlook - Management highlighted a challenging macro and operating environment but expressed confidence in the stability provided by the China business [6] - The focus for 2026 is on maintaining the strength of the existing business while preparing for multiple growth opportunities, including the launch of KarXT and advancing late-stage assets [19] - Management emphasized the importance of disciplined spending and maintaining a strong cash position to support future growth [21] Other Important Information - The company has a strong cash position, ending the quarter with $790 million, which positions it well for executing its priorities [21] - The company is focused on expanding its global pipeline while preserving financial flexibility for future investments [46] Q&A Session Summary Question: Can you provide any color on how we should be thinking about revenues and expenses for 2026? - Management expects good growth opportunities for VYVGART and ZEJULA, with modest investments required to support launches [24] Question: Can you remind us of the implications of the intracranial activity in patients with brain mets for Zoci? - Zoci has shown an 80% response rate in patients with untreated brain metastases, which is a significant advantage [29] Question: Can you elaborate on the U.S., China development model? - The company is applying its efficient development structure in China to global trials, allowing for faster and higher quality execution [34] Question: What should we expect from KarXT in 2026 and 2027? - The commercial launch of KarXT is expected in the second quarter of 2026, with a focus on building disease awareness and establishing clinical confidence [73] Question: What is the expectation for completion of enrollment for Zoci? - Enrollment is expected to be completed by the end of the first quarter of next year, with a goal for accelerated approval in 2028 [48]

Summary of Zai Lab's Conference Call Company Overview - **Company**: Zai Lab - **Focus Areas**: Oncology and Immunology - **Key Product**: Zosi, a DLL3-targeted antibody-drug conjugate (ADC) Key Points on Zosi Development - **Clinical Trials**: - Initiated a global phase three trial for Zosi in second-line small cell lung cancer (SCLC) and expanding into first-line SCLC and neuroendocrine carcinomas (NECs) [2][5][18] - Zosi has shown a 68% overall response rate (ORR) in second-line patients at a dose of 1.6 mg/kg and an 80% ORR in patients with untreated brain metastases [4][14] - The median duration of response is 6.1 months across all doses [15] - **Safety Profile**: - Zosi demonstrated a low rate of grade three treatment-related adverse events at 13%, significantly lower than other ADCs [12] - No treatment discontinuations due to toxicity were reported [16] - **Patient Population**: - The trial includes heavily pretreated patients, with over 90% having received prior anti-PD-L1 or PD-1 therapy [11] - Approximately one-third of patients had brain metastases, which is significant given the poor prognosis associated with this condition [11][52] Market Context and Competitive Landscape - **Urgent Need for New Therapies**: - SCLC accounts for about 15% of lung cancer cases, with over 370,000 new cases annually worldwide [6] - Current treatment options are limited and often associated with high toxicity and poor long-term outcomes [7][8] - **Positioning Against Competitors**: - Zosi is positioned as a chemotherapy-sparing option, which could enhance its appeal in the first-line treatment setting [26][34] - The competitive landscape includes Imdeltra, which is expected to become a front-line agent, but Zosi's rapid onset of action and favorable safety profile may provide a competitive edge [25][34] Future Development Plans - **Upcoming Trials**: - A randomized phase two study is ongoing to optimize dose selection, with plans for a pivotal study in the front-line setting in 2026 [19][48] - Zai Lab is also exploring combination strategies with other agents to enhance Zosi's efficacy [58] - **Regulatory Strategy**: - Zai Lab aims for accelerated approval based on response and durability of response, with a potential filing in 2027 [23][41] - The FDA has agreed on the focus doses of 1.2 and 1.6 mg/kg for the pivotal trial [45] Additional Insights - **Brain Metastasis Efficacy**: - Zosi has shown promising results in patients with brain metastases, with an 80% response rate, highlighting its potential for treating this challenging aspect of SCLC [52][54] - **Long-term Vision**: - Zai Lab is committed to reshaping the treatment paradigm for SCLC and NECs, with a focus on delivering innovative therapies that improve patient outcomes [19][60] Conclusion - Zai Lab is advancing Zosi as a potential best-in-class treatment for SCLC, with a strong emphasis on safety, efficacy, and rapid development timelines. The company is well-positioned to address significant unmet needs in oncology, particularly in challenging patient populations.